Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC [0.03%]
严重放疗引起的淋巴细胞减少减弱了同步放化疗后Durvalumab治疗NSCLC的效果
Wang Jing,Ting Xu,Lirong Wu et al.
Wang Jing et al.
Introduction: Durvalumab after concurrent chemoradiation (CCRT) for NSCLC improves survival, but only in a subset of patients. We investigated the effect of severe radiation-induced lymphopenia (sRIL) on survival in these...
Complementary Roles for Tissue- and Blood-Based Comprehensive Genomic Profiling for Detection of Actionable Driver Alterations in Advanced NSCLC [0.03%]
组织和血液综合基因组检测在晚期非小细胞肺癌患者中发现可操作驱动突变的互补作用
Lee S Schwartzberg,Gerald Li,Khaled Tolba et al.
Lee S Schwartzberg et al.
Introduction: Whereas tumor biopsy is the reference standard for genomic profiling of advanced NSCLC, there are now multiple assays approved by the Food and Drug Administration for liquid biopsy testing of circulating tum...
One-Year Incidences of Venous Thromboembolism, Bleeding, and Death in Patients With Lung Cancer (Cancer-VTE Subanalysis) [0.03%]
肺癌患者VTE、出血和死亡的一年发生率（Cancer-VTE子分析）
Nobuyasu Awano,Tetsuya Okano,Riken Kawachi et al.
Nobuyasu Awano et al.
Introduction: This subanalysis aimed to provide real-world data on venous thromboembolism (VTE) from patients with lung cancer in the Cancer-VTE Registry. ...
A Real-World Analysis of Immune Checkpoint Inhibitor-Based Therapy After Osimertinib Treatment in Patients With EGFR-Mutant NSCLC [0.03%]
奥希替尼治疗后使用免疫检查点抑制剂治疗EGFR突变型非小细胞肺癌患者的现实世界分析
Kenji Morimoto,Ryo Sawada,Tadaaki Yamada et al.
Kenji Morimoto et al.
Introduction: The use of immune checkpoint inhibitors (ICIs) with chemotherapy has increased the survival of patients with advanced NSCLC. Nevertheless, the efficacy of ICI treatment for NSCLC with EGFR mutations is limit...
Characterization of MET Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing [0.03%]
通过全转录组测序表征非小细胞肺癌中MET外显子14跳跃突变及鉴定潜在治疗靶点
So Yeon Kim,Jun Yin,Stephen Bohlman et al.
So Yeon Kim et al.
Introduction: Genomic alterations in the juxtamembrane exon 14 splice sites in NSCLC lead to increased MET stability and oncogenesis. We present the largest cohort study of MET Exon 14 (METex14) using whole transcriptome ...
Role of 3'-Deoxy-3'-[18F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase [0.03%]
丙氩亚氨苷酶治疗的精氨琥珀酸合成酶1缺陷型胸部癌症中,3'-脱氧-3'-(18F)氟胸腺嘧啶正电子发射断层成像-X线计算机断层摄影预测标志物的作用研究
Teresa A Szyszko,Joel T Dunn,Melissa M Phillips et al.
Teresa A Szyszko et al.
Introduction: Pegargiminase (ADI-PEG 20I) degrades arginine in patients with argininosuccinate synthetase 1-deficient malignant pleural mesothelioma (MPM) and NSCLC. Imaging with proliferation biomarker 3'-deoxy-3'-[18F] ...
First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan [0.03%]
PD-L1高表达的晚期NSCLC患者一线使用帕博利珠单抗单药治疗的日本真实世界研究（纳入老年人群）
Yasushi Goto,Atsuhisa Tamura,Hirotaka Matsumoto et al.
Yasushi Goto et al.
Introduction: Pembrolizumab became available in Japan in February 2017 for first-line monotherapy of unresectable advanced and metastatic NSCLC with programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) greater t...
Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials [0.03%]
brigatinib治疗克唑替尼耐药的ALK阳性非小细胞肺癌患者的长期疗效和安全性：Ⅰ期/Ⅱ期和随机Ⅱ期（ALTA）临床试验最终结果
Scott N Gettinger,Rudolf M Huber,Dong-Wan Kim et al.
Scott N Gettinger et al.
Introduction: We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK-rearrangement positive (ALK+) NSCLC. Meth...
A High Percentage of NSCLC With Germline CHEK2 Mutation Harbors Actionable Driver Alterations: Survey of a Cancer Genomic Database and Review of Literature [0.03%]
高比例的非小细胞肺癌GERMLINE CHEK2突变型携带可操作驱动基因改变：癌症基因组数据库调查及文献综述
Shannon S Zhang,Jessica K Lee,Hanna Tukachinsky et al.
Shannon S Zhang et al.
Introduction: Germline CHEK2 mutations are rare and have not been associated with increased risk of NSCLC. Methods: We identified two s...
Moving the Needle Cautiously in Targeting One of the Most Often Acquired Receptor Tyrosine Fusion (RET Fusion) Resistance Mechanisms to EGFR Tyrosine Kinase Inhibitors [0.03%]
EGFR酪氨酸激酶抑制剂耐药机制中最为常见的受体酪氨酸融合蛋白（RET融合蛋白）的潜在靶向治疗展望
Shannon S Zhang,Sai-Hong Ignatius Ou
Shannon S Zhang